These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31081381)

  • 1. From the margins to mainstream: How providers of autologous 'stem cell treatments' legitimise their practice in Australia.
    MacGregor C; Petersen A; Munsie M
    Health (London); 2021 Jan; 25(1):51-68. PubMed ID: 31081381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The direct-to-consumer market for stem cell-based interventions in Australia: exploring the experiences of patients.
    Waldby C; Hendl T; Kerridge I; Lipworth W; Lysaght T; Munsie M; Stewart C
    Regen Med; 2020 Jan; 15(1):1238-1249. PubMed ID: 32009513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Professional regulation: a potentially valuable tool in responding to "stem cell tourism".
    Zarzeczny A; Caulfield T; Ogbogu U; Bell P; Crooks VA; Kamenova K; Master Z; Rachul C; Snyder J; Toews M; Zoeller S
    Stem Cell Reports; 2014 Sep; 3(3):379-84. PubMed ID: 25241736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions.
    Ogbogu U; Du J; Koukio Y
    BMC Med Ethics; 2018 May; 19(1):32. PubMed ID: 29716594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The roles and responsibilities of physicians in patients' decisions about unproven stem cell therapies.
    Levine AD; Wolf LE
    J Law Med Ethics; 2012; 40(1):122-34. PubMed ID: 22458467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Between hope and evidence: how community advisors demarcate the boundary between legitimate and illegitimate stem cell treatments.
    Petersen A; Tanner C; Munsie M
    Health (London); 2015 Mar; 19(2):188-206. PubMed ID: 25367895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulating the advertising and promotion of stem cell therapies.
    von Tigerstrom B
    Regen Med; 2017 Oct; 12(7):815-826. PubMed ID: 29112482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chinese newspaper coverage of (unproven) stem cell therapies and their providers.
    Ogbogu U; Du L; Rachul C; Bélanger L; Caulfield T
    Stem Cell Rev Rep; 2013 Apr; 9(2):111-8. PubMed ID: 23292462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia.
    McLean AK; Stewart C; Kerridge I
    Stem Cell Res Ther; 2015 Feb; 6(1):33. PubMed ID: 25689404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open for business: a comparative study of websites selling autologous stem cells in Australia and Japan.
    Munsie M; Lysaght T; Hendl T; Tan HL; Kerridge I; Stewart C
    Regen Med; 2017 Oct; 12(7):777-790. PubMed ID: 29125016
    [No Abstract]   [Full Text] [Related]  

  • 11. Rogue stem cell clinics.
    Murray IR; Chahla J; Frank RM; Piuzzi NS; Mandelbaum BR; Dragoo JL;
    Bone Joint J; 2020 Feb; 102-B(2):148-154. PubMed ID: 32009438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Australian regulation of autologous human cell and tissue products: implications for commercial stem cell clinics.
    Ghinea N; Munsie M; Rudge C; Stewart C
    Regen Med; 2020 Feb; 15(2):1361-1369. PubMed ID: 32228372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions.
    Turner L
    Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Industry Responsibilities in Tackling Direct-to-Consumer Marketing of Unproven Stem Cell Treatments.
    Master Z; Fu W; Paciulli D; Sipp D
    Clin Pharmacol Ther; 2017 Aug; 102(2):177-179. PubMed ID: 28695633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vulnerabilities and the Use of Autologous Stem Cells for Medical Conditions in Australia.
    Hendl T
    Perspect Biol Med; 2018; 61(1):76-89. PubMed ID: 29805149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging global themes in the bioethics of regenerative medicine: the tangled web of stem cell translation.
    Chan S
    Regen Med; 2017 Oct; 12(7):839-851. PubMed ID: 29119870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International stem cell tourism and the need for effective regulation. Part I: Stem cell tourism in Russia and India: clinical research, innovative treatment, or unproven hype?
    Cohen CB; Cohen PJ
    Kennedy Inst Ethics J; 2010 Mar; 20(1):27-49. PubMed ID: 20506693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selling stem cell 'treatments' as research: prospective customer perspectives from crowdfunding campaigns.
    Snyder J; Turner L
    Regen Med; 2018 Jun; 13(4):375-384. PubMed ID: 29985757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory loophole enables unproven autologous cell therapies to thrive in Australia.
    Munsie M; Pera M
    Stem Cells Dev; 2014 Dec; 23 Suppl 1():34-8. PubMed ID: 25457959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.